Cardiometabolic Disorders

Top Story

DEVOTE: Insulin degludec demonstrates CV safety, reduced risk for severe hypoglycemia

DEVOTE: Insulin degludec demonstrates CV safety, reduced risk for severe hypoglycemia
June 21, 2017

SAN DIEGO — In the DEVOTE cardiovascular outcomes trial, insulin degludec was noninferior to insulin glargine for the primary endpoint of major adverse cardiovascular events and was associated with significant reductions in severe hypoglycemia among high-risk patients with type 2 diabetes.

The randomized, double blind, treat-to-target, event-driven, CV outcomes trial included 7,637 patients with type 2 diabetes enrolled at 436 sites in 20 countries between October 2013 and November 2014. Researchers randomly assigned 3,818 patients to receive insulin degludec 100 U/mL (Tresiba, Novo Nordisk), a new-generation, ultra-long-acting basal insulin, and 3,819 to receive insulin glargine U100 (Lantus, Sanofi), a first-generation insulin, once per day between dinner and bedtime.

In the Journals Plus

ARIC analysis: Thyroid dysfunction does not increase risk for CVD

June 19, 2017
Middle-aged adults with varying degrees of hypothyroidism and hyperthyroidism have a cardiovascular risk profile that is similar to those without thyroid dysfunction…
Meeting News

CVD-REAL: SGLT2 inhibitors benefit patients with diabetes, irrespective of CV history

June 14, 2017
SAN DIEGO — Treatment with an SGLT2 inhibitor was associated with lower rates of death and heart failure compared with other glucose-lowering drugs, regardless of…
Meeting News

Global burden of diabetes complications ‘substantial,’ continues to grow

June 13, 2017
SAN DIEGO — The global burden of microvascular and macrovascular complications in adults with type 2 diabetes is relatively high and is expected to grow as the…
CME

Improving Bone Strength and Reducing Fracture Risk in Osteoporosis

This activity is supported by an educational grant from Merck & Co., Inc.

Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue leading to reduced…
More »
Video
Meeting News Coverage

VIDEO: PEGASUS-TIMI 54 analysis shows reduced risk for MACE in patients with diabetes

April 7, 2016
More »
Featured
The Endocrine Society Annual Meeting

The Endocrine Society Annual Meeting

CME

Practical Lipidology®: Volume 3, Number 2

This activity is supported by an educational grant from Amgen

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing…
More »
Meeting News

DEVOTE: Insulin degludec demonstrates CV safety, reduced risk for severe hypoglycemia

June 21, 2017
SAN DIEGO — In the DEVOTE cardiovascular outcomes trial, insulin degludec was noninferior to insulin glargine for the primary endpoint of major…

In the Journals Plus

ARIC analysis: Thyroid dysfunction does not increase risk for CVD

June 19, 2017
Middle-aged adults with varying degrees of hypothyroidism and hyperthyroidism have a cardiovascular risk profile that is similar to those without…

Meeting News

CVD-REAL: SGLT2 inhibitors benefit patients with diabetes, irrespective of CV history

June 14, 2017
SAN DIEGO — Treatment with an SGLT2 inhibitor was associated with lower rates of death and heart failure compared with other glucose-lowering…

Meeting News

Global burden of diabetes complications ‘substantial,’ continues to grow

June 13, 2017
SAN DIEGO — The global burden of microvascular and macrovascular complications in adults with type 2 diabetes is relatively high and is…

Meeting News

Risk for major adverse CV events modest with prediabetes

June 13, 2017
SAN DIEGO — Adults with prediabetes have a modestly increased risk for major adverse cardiovascular events, while younger patients with…

Meeting News

LEADER: Baseline CVD medication use does not explain liraglutide CV benefit

June 12, 2017
SAN DIEGO — Further analyses of results from the LEADER trial revealed that baseline HbA1c, cardiovascular medication use and…

Meeting News

PCSK9 inhibitor lowers CV risk in insulin-treated type 2 diabetes

June 11, 2017
SAN DIEGO — Results of the ODYSSEY DM-INSULIN trial indicate that adults with dyslipidemia and type 2 diabetes who are taking insulin can…

In the Journals Plus

Elevated triglycerides ‘predominant marker’ for disrupted circadian rhythms in older adults

June 8, 2017
In older adults with overweight or obesity, elevated triglyceride levels are associated with increased circadian rhythm disruption, measured by…

Meeting News

Some diabetes drugs reduce CV risks, but clinical judgment required

June 2, 2017
PHILADELPHIA — Clinical trials support that certain glucose-lowering agents for diabetes reduce the risk for CVD. However, clinical judgment

In the Journals Plus

Decrease in free T4 increases metabolic syndrome risk

June 2, 2017
The risk for metabolic syndrome may rise with decreasing serum free thyroxine levels, particularly in adults without obesity, according to findings…

More Headlines »
Advertisement
Advertisement